Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MH048 in Relapsed/Refractory B-cell Malignancies
NCT04689308Phase 1Unknown
- Sponsor
- Minghui Pharmaceutical, Inc.
- Start
- Jan 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of MH048 in B cell malignancies, sponsored by Minghui Pharmaceutical, Inc. Primary endpoints: Treatment-Emergent Adverse Events up to 24 Months, Maximum Tolerated Dose and 1 more. Status: unknown.
02
Drugs
MH048
03
Conditions
B cell malignancies
Beyond the preview
Go deeper on NCT04689308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04689308.